<DOC>
	<DOCNO>NCT01002807</DOCNO>
	<brief_summary>To assess relative bioavailability dapagliflozin metformin two FDC formulation , comprise 10 mg dapagliflozin 1000 mg metformin XR , relative coadministration dapagliflozin 10 mg tablet 2 x 500 mg GlucophageÂ® XR tablet , healthy subject fast state .</brief_summary>
	<brief_title>Bioavailability Study Fixed Dose Combination ( FDC ) Formulations Dapagliflozin Metformin XR Versus Individual Component Coadministered Healthy Subjects Fasted State</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Men woman age 18 45 inclusive Healthy subject determine clinically significant deviation normal medical history , physical examination , ECGs , clinical laboratory determination Body Mass Index ( BMI ) 18 32 kg/m2 , inclusive . BMI = weight ( kg ) / [ height ( ) ] 2 WOCBP unwilling unable use acceptable method avoid pregnancy entire study period 8 week last dose investigational product Any significant acute chronic medical illness Current recent ( within 3 month ) gastrointestinal disease Any major surgery within 4 week study drug administration Glucosuria screen Abnormal liver function test ( ALT , AST total bilirubin &gt; 10 % ULN ) Presence edema physical exam History diabetes mellitus History heart failure History renal insufficiency History chronic recurrent UTI ( define 3 occurrence per year ) UTI past 3 month History recurrent ( defined 3 occurrence per year ) recent vulvovaginal mycotic infection Estimated creatinine clearance ( ClCR ) &lt; 80 mL/min use Cockcroft Gault formula History allergy intolerance metformin similar agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>